Co-Sentor tab. p / captivity. about. 50mg/12.5mg in bl. in pack. №10х3

Co-Sentor Tablets: Comprehensive Information for Effective Blood Pressure Management

Description: Co-Sentor® is a combination medication containing losartan potassium, an angiotensin II receptor antagonist (ARB), and hydrochlorothiazide, a thiazide diuretic. It is available in three strengths: 50mg/12.5mg, 100mg/12.5mg, and 100mg/25mg.

Key Features:

• Effective Blood Pressure Control: Co-Sentor® provides additive blood pressure lowering effects compared to its individual components.
• 24-Hour Action: The antihypertensive effect of Co-Sentor® lasts for 24 hours, ensuring consistent blood pressure control.
• Minimal Heart Rate Impact: Unlike some other antihypertensive medications, Co-Sentor® has minimal impact on heart rate.
• Diverse Patient Population: Co-Sentor® is effective for various patient demographics, including men and women, different races, and different age groups.

Composition:

• Co-Sentor® 50/12.5 mg:
  • Active Ingredients: Losartan potassium – 50 mg; Hydrochlorothiazide – 12.5 mg.
  • Excipients: Magnesium stearate, pregelatinized starch, lactose monohydrate, microcrystalline cellulose, Opadry II 85F23426 orange (iron oxide black E 172, sunset yellow E 110, iron oxide yellow E 172, talc, macrogol 3350, titanium dioxide E 171, polyvinyl alcohol).
• Co-Sentor® 100/12.5 mg:
  • Active Ingredients: Losartan potassium – 100 mg; Hydrochlorothiazide – 12.5 mg.
  • Excipients: Magnesium stearate, pregelatinized starch, lactose monohydrate, microcrystalline cellulose, Opadry II 85F27044 yellow (iron oxide black E 172, sunset yellow E 110, iron oxide yellow E 172, talc, macrogol 3350, titanium dioxide (E 171), polyvinyl alcohol).
• Co-Sentor® 100/25 mg:
  • Active Ingredients: Losartan potassium – 100 mg; Hydrochlorothiazide – 25 mg.
  • Excipients: Magnesium stearate, pregelatinized starch, lactose monohydrate, microcrystalline cellulose, Opadry II 85F23426 orange (iron oxide black E 172, sunset yellow E 110, iron oxide yellow E 172, talc, macrogol 3350, titanium dioxide E 171, polyvinyl alcohol).

Pharmacological Action:

• Losartan:
  • Blocks the effects of angiotensin II, a hormone that constricts blood vessels.
  • Reduces peripheral vascular resistance, blood pressure, and pressure in the pulmonary circulation.
  • Prevents myocardial hypertrophy and improves exercise tolerance in heart failure.
• Hydrochlorothiazide:
  • Increases sodium and water excretion, reducing blood volume.
  • Alters vascular wall reactivity and reduces the effect of vasoconstrictor substances.
  • Provides a diuretic effect that lasts for 6 to 12 hours.

Indications:

• Treatment of high blood pressure in patients who require combination therapy.
• Reducing cardiovascular disease risk and mortality in patients with high blood pressure and left ventricular hypertrophy.

Contraindications:

• Hypersensitivity to losartan, hydrochlorothiazide, or any component of the drug.
• Untreated hypokalemia or hypercalcemia.
• Severe liver failure.
• Cholestasis or obstruction of the biliary tract.
• Refractory hyponatremia.
• Symptomatic hyperuricemia/gout.
• Severe renal failure (creatinine clearance < 30 ml/min).
• Anuria.
• Severe arterial hypotension.
• Hypovolemia (including due to high doses of diuretics).
• Pregnancy and lactation.
• Age up to 18 years.

Precautions:

• Bilateral renal artery stenosis or stenosis of the artery of a single kidney.
• Hypovolemia (including diarrhea, vomiting).
• Hyponatremia (increased risk of hypotension in patients on a low-salt diet).
• Hypochloremic alkalosis.
• Hypomagnesemia.
• Hypokalemia.
• Connective tissue diseases (including systemic lupus erythematosus).
• Diabetes mellitus.
• Gout.
• Bronchial asthma.
• Aggravated allergic history.
• Hyperuricemia.
• Hypercalcemia.
• Mild to moderate hepatic insufficiency.
• Aortic or mitral valve stenosis.
• Obstructive hypertrophic cardiomyopathy.
• Concomitant use with NSAIDs, including COX-2 inhibitors.

Dosage and Administration:

• Oral administration, regardless of meals, with a glass of water.
• Initial and maintenance dose: 50 mg losartan + 12.5 mg hydrochlorothiazide (1 tablet of Co-Sentor®) per day.
• Dose may be increased to 100mg/12.5mg or 100mg/25mg per day, depending on blood pressure control.
• Maximum dose: One tablet of Co-Sentor® 100mg/25mg once a day.
• Antihypertensive effect typically achieved within 3-4 weeks of therapy.

Side Effects:

• Most common: Dizziness, headache, fatigue, asthenia.
• Other potential side effects include:
  • Blood and lymphatic system disorders: Anemia, ecchymosis, hemolysis.
  • Immune system disorders: Anaphylactic reactions, angioedema, urticaria.
  • Nervous system disorders: Insomnia, anxiety, depression, tremor, syncope.
  • Cardiovascular disorders: Hypotension, orthostatic hypotension, arrhythmias.
  • Respiratory disorders: Cough, nasal congestion, sinusitis.
  • Gastrointestinal disorders: Abdominal pain, nausea, diarrhea, dyspepsia.
  • Skin disorders: Alopecia, dermatitis, rash, pruritus.
  • Musculoskeletal disorders: Muscle cramps, back pain, myalgia.

Drug Interactions:

• Co-administration with drugs that lower blood pressure may increase the risk of hypotension.
• Potassium-sparing diuretics, potassium preparations, and salt substitutes containing potassium may increase potassium levels.
• Lithium preparations may increase lithium levels.
• NSAIDs, including COX-2 inhibitors, may reduce the antihypertensive effect of losartan.
• Thiazide diuretics may interact with various drugs, including barbiturates, hypoglycemic agents, other antihypertensive drugs, pressor amines, non-depolarizing muscle relaxants, lithium preparations, drugs used to treat gout, anticholinergics, cytotoxic agents, salicylates, methyldopa, cyclosporine, digitalis preparations, and drugs affected by changes in serum potassium.

Overdose:

• Symptoms: Pronounced hypotension, tachycardia, bradycardia, loss of electrolytes (hypokalemia, hypochloremia, hyponatremia), dehydration.
• Treatment: Symptomatic and supportive therapy, gastric lavage, correction of water and electrolyte imbalances.

Important Considerations:

• Use with caution in patients with reduced circulating blood volume or hyponatremia.
• Monitor electrolyte levels regularly in patients with renal insufficiency.
• Use with caution in patients with hepatic insufficiency.
• Do not use in patients with severe hepatic impairment.
• Monitor potassium levels and creatinine clearance in patients with heart failure.
• Avoid use with potassium-sparing diuretics, potassium supplements, and salt substitutes.
• Use with caution in patients with bilateral renal artery stenosis or stenosis of the artery of a single kidney.
• Avoid dual blockade of the RAAS.
• Use with caution in patients with coronary artery disease or cerebrovascular disease.
• Use with caution in patients with heart failure.
• Use with caution in patients with aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.
• Monitor for ethnic differences in response to therapy.

Disclaimer: This information is intended for general knowledge and does not constitute medical advice. Please consult with your doctor or healthcare provider for personalized advice, diagnosis, and treatment.